biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > British Columbia Securities Commission!!

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 07, 2023 12:20pm

213 Views

Post# 35272041

RE:RE:RE:RE:RE:RE:British Columbia Securities Commission!!

It will be very interesting to see what happens next. BTI is in a very difficult situation on one side of the equation; but Rathjen has been the most dynamic CEO that BTI has ever had. She has completed more deals, bigger deals, more tranformative deals and came close to closing the biggest and most transformative deal in BTI's history with Biodexa. The deal was so big it literally had the Former Group Finance Director of Shire challenging anyone to find a company its size with greater opportunity. That literlly happened! Biodexa would have been a potential multi-platform powerhouse. In the Biodexa deal Rathjen demonstrated a willingness to think incredibly BIG. The deal even had potentially US$20 million in cash lined up from a successful fund like Armistice Capital during the worst biotech bear market in history. The largest healthcare company in the world, J&J, may have also just extended, expanded, and paid a small milestone for xB3 as Chiesi is potentially on the verge of becoming a strategic player in Lysosomal Storage Disease. What will Rathjen's next move be?

G1945V wrote:
zwerp2000 wrote: what else would Lind do? BTI has no money. They can't pay back the debt they owe to them.

Surely, if push comes to shove, insiders can put a million dollars together to keep the IPs away from Lind.

G1945V